AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30095773 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized oxycodone prescription
Number of subjects: 172
Study 30095773 — intervention group
Group type: COMPARATOR
Intervention: Standard oxycodone prescription
Number of subjects: 172
Study 27159341 — intervention group
Group type: COMPARATOR
Intervention: Varenicline 2mg/d
Number of subjects: 60
Study 27159341 — intervention group
Group type: COMPARATOR
Intervention: Varenicline 1mg/d
Number of subjects: 60
Study 27159341 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma varenicline levels ≥3ng/mL
Number of subjects: 60
Study 27159341 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma varenicline levels ≥5ng/mL
Number of subjects: 60
Study 25393358 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) guided access
Number of subjects: 64
Study 25393358 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopic guided access
Number of subjects: 64
Study 22178347 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic extraperitoneal adenomectomy (LEA)
Number of subjects: 46
Study 22178347 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 46
Study 20194013 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin 5-unit bolus and placebo infusion
Number of subjects: 74
Study 20194013 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 5-unit bolus and oxytocin 30-unit infusion
Number of subjects: 74
Study 17638549 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diclofenac sodium (50 mg for body weight <70 kg; 100 mg for body weight >70 kg) 60 minutes prior to SWL
Number of subjects: 240
Study 17638549 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical EMLA (5 g) 60 minutes prior to SWL
Number of subjects: 240
Study 17638549 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral diclofenac sodium and topical EMLA (5 g) 60 minutes prior to SWL
Number of subjects: 240
Study 16079682 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist with arteriovenous fistula
Number of subjects: 279
Study 16079682 — intervention group
Group type: COMPARATOR
Intervention: Contralateral wrist (control)
Number of subjects: 279
Study 16079682 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of fistula
Number of subjects: 279
Study 16079682 — intervention group
Group type: EXPERIMENTAL
Intervention: Site of fistula (snuffbox, radiocephalic)
Number of subjects: 279
Study 16079682 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodiagnostic studies
Number of subjects: 279
Study 11061518 — intervention group
Group type: COMPARATOR
Intervention: Standard recombinant human GH therapy (0.3 mg/kg x week)
Number of subjects: 97
Study 11061518 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose recombinant human GH therapy (0.7 mg/kg x week)
Number of subjects: 97
Study 9279533 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide 10 mg
Number of subjects: 12
Study 9279533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8336373 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment (chlorthalidone, acebutolol, doxazosin mesylate, amlodipine maleate, enalapril maleate)
Number of subjects: 731
Study 8336373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 731
Study 8336373 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment (all drug groups combined)
Number of subjects: 731
Study 3459351 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard gemfibrozil dosage of two 300-mg capsules 2 times a day (total 1200 mg daily)
Number of subjects: 321
Study 3459351 — intervention group
Group type: EXPERIMENTAL
Intervention: 600-mg tablet of gemfibrozil 2 times a day (total 1200 mg daily)
Number of subjects: 321
Study 3459351 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 450-mg tablets of gemfibrozil once a day in the evening
Number of subjects: 321
Study 2968669 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine capsule (burst dose regimen)
Number of subjects: 27
Study 2968669 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 27
Study 31064666 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid oral nutritional supplement (ONS)
Number of subjects: 17
Study 31064666 — intervention group
Group type: COMPARATOR
Intervention: Semi solid inbetween meal snack (snack)
Number of subjects: 17
Study 29474130 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing a prime-time television clip depicting public breastfeeding
Number of subjects: 375
Study 29474130 — intervention group
Group type: EXPERIMENTAL
Intervention: Entertainment media messages
Number of subjects: 375
Study 29101841 — intervention group
Group type: EXPERIMENTAL
Intervention: One Session Treatment (OST)
Number of subjects: 165
Study 29101841 — intervention group
Group type: COMPARATOR
Intervention: Educational Support Therapy (C)
Number of subjects: 165
Study 29101841 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 165
Study 25933976 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate (220 mg containing 50mg zinc element) for 12 weeks
Number of subjects: 43
Study 25933976 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 43
Study 23328851 — intervention group
Group type: EXPERIMENTAL
Intervention: Forefoot off‐loading postoperative shoe (FOPS)
Number of subjects: 14
Study 23328851 — intervention group
Group type: COMPARATOR
Intervention: Control shoe
Number of subjects: 14
Study 23328851 — intervention group
Group type: EXPERIMENTAL
Intervention: Forefoot off‐loading postoperative shoe (FOPS) with contralateral shoe raise
Number of subjects: 14
Study 21284697 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Patch (Nicotinell Patch 10cm(2), 17.5mg nicotine, average delivery rate 7mg/24h)
Number of subjects: 90
Study 19307503 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed 500 mg/m² (arm A)
Number of subjects: 240
Study 19307503 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m² plus carboplatin AUC 5 (arm B)
Number of subjects: 240
Study 19307503 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MTHFR C677T homozygous mutation
Number of subjects: 240
Study 17073957 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydioxanone (PDS) suture
Number of subjects: 366
Study 17073957 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel (SS) sternal approximation
Number of subjects: 366
Study 15085019 — intervention group
Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 4
Study 15085019 — intervention group
Group type: EXPERIMENTAL
Intervention: Control formula with medium-chain triglyceride and dextrinomaltose (group A: 33:66 ratio)
Number of subjects: 4
Study 15085019 — intervention group
Group type: EXPERIMENTAL
Intervention: Control formula with medium-chain triglyceride and dextrinomaltose (group B: 66:33 ratio)
Number of subjects: 4
Study 15085019 — intervention group
Group type: EXPERIMENTAL
Intervention: Control formula with medium-chain triglyceride and dextrinomaltose (group C: 85:15 ratio)
Number of subjects: 4
Study 15085019 — intervention group
Group type: COMPARATOR
Intervention: Control formula (group D)
Number of subjects: 4
Study 11134438 — intervention group
Group type: COMPARATOR
Intervention: Oral iron group (9 mg/kg/day of iron polymaltose complex)
Number of subjects: 29
Study 11134438 — intervention group
Group type: COMPARATOR
Intervention: EPO + oral iron group (300 U of recombinant human EPO kg/day and daily oral IPC)
Number of subjects: 29
Study 11134438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron + EPO group (2 mg/kg/day of intravenous iron sucrose, r‐HuEPO, and oral iron)
Number of subjects: 29
Study 9205169 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstructed ascending aorta
Number of subjects: 22
Study 9205169 — intervention group
Group type: COMPARATOR
Intervention: Nonreconstructed aorta
Number of subjects: 22
Study 9205169 — intervention group
Group type: EXPERIMENTAL
Intervention: Descending aorta (both reconstructed and nonreconstructed)
Number of subjects: 22
Study 8381146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional vinblastine
Number of subjects: 11
Study 8381146 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate buffered lidocaine (BBL)
Number of subjects: 11
Study 8381146 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine mixed with BBL
Number of subjects: 11
Study 8381146 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine 5 minutes after BBL injection
Number of subjects: 11
Study 8381146 — intervention group
Group type: COMPARATOR
Intervention: Control lesions (BBL, saline, or no treatment)
Number of subjects: 11
Study 3302110 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg/day
Number of subjects: 25
Study 3302110 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg/day
Number of subjects: 25
Study 3302110 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg/day
Number of subjects: 25
Study 31675595 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal taping (muscle application over peroneus longus)
Number of subjects: 30
Study 31675595 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal-distal taping (muscle application over gluteus medius and peroneus longus)
Number of subjects: 30
Study 31675595 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study 27909231 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT and nitrate-rich beetroot juice (13 mmol/day) (SIT+BR)
Number of subjects: 36
Study 27909231 — intervention group
Group type: COMPARATOR
Intervention: SIT and nitrate-depleted beetroot juice as a placebo (SIT+PL)
Number of subjects: 36
Study 27909231 — intervention group
Group type: EXPERIMENTAL
Intervention: No training and nitrate-rich beetroot juice (NT+BR)
Number of subjects: 36
Study 25792254 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional transbronchial needle aspiration (TBNA)
Number of subjects: 100
Study 25792254 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound-guided TBNA (EBUS‐TBNA)
Number of subjects: 100
Study 25792254 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided fine needle aspiration (EUS‐FNA)
Number of subjects: 100
Study 23718639 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic cathinones (bath salts)
Number of subjects: 2349
Study 23718639 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 2349
Study 23718639 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanics and Native Americans
Number of subjects: 2349
Study 23718639 — intervention group
Group type: EXPERIMENTAL
Intervention: Student athletes
Number of subjects: 2349
Study 23718639 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic cathinones
Number of subjects: 2349
Study 21295507 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 39
Study 19093004 — intervention group
Group type: EXPERIMENTAL
Intervention: PfAMA1 with Alhydrogel
Number of subjects: 60
Study 19093004 — intervention group
Group type: EXPERIMENTAL
Intervention: PfAMA1 with Montanide ISA720
Number of subjects: 60
Study 19093004 — intervention group
Group type: EXPERIMENTAL
Intervention: PfAMA1 with AS02
Number of subjects: 60
Study 19093004 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations (PfAMA1 with Alhydrogel, Montanide ISA720, AS02)
Number of subjects: 60
Study 16966690 — intervention group
Group type: EXPERIMENTAL
Intervention: Belagenpumatucel-L (1.25, 2.5, or 5.0 x 10(7) cells/injection) administered monthly or every other month for a maximum of 16 injections
Number of subjects: 75
Study 14582545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannulated screws combined with calcium‐phosphate cement for augmentation
Number of subjects: 40
Study 14582545 — intervention group
Group type: COMPARATOR
Intervention: Cannulated screws alone (controls)
Number of subjects: 40
Study 10699943 — intervention group
Group type: EXPERIMENTAL
Intervention: T+GLA (Gamma linolenic acid with tamoxifen 20 mg od)
Number of subjects: 38
Study 10699943 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg od alone
Number of subjects: 38
Study 9356093 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 201
Study 9356093 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 201
Study 8411294 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard auricular acupuncture treatment
Number of subjects: 100
Study 8411294 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (geographically close points)
Number of subjects: 100
Study 3092937 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphinpyrazone
Number of subjects: 25
Study 3092937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31895658 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine n-3 fatty acids (1 g/d)
Number of subjects: 25871
Study 31895658 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/d)
Number of subjects: 25871
Study 29530933 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (1 or 2 years; N = 561)
Number of subjects: 862
Study 29530933 — intervention group
Group type: COMPARATOR
Intervention: Observation (N = 301)
Number of subjects: 862
Study 29530933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclin D1 (as continuous variable)
Number of subjects: 862
Study 29530933 — intervention group
Group type: EXPERIMENTAL
Intervention: TOP2A, Ki67, and cyclin D1 (as categorical variables)
Number of subjects: 862
Study 27069071 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 sessions of manualized family intervention
Number of subjects: 620
Study 27069071 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 620
Study 27069071 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 sessions of manualized family intervention
Number of subjects: 620
Study 24973609 — intervention group
Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 42
Study 22352443 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Loss Scores derived from the first group (n = 50)
Number of subjects: 100
Study 22352443 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Loss Scores validated against the second group (n = 50)
Number of subjects: 100
Study 19853420 — intervention group
Group type: EXPERIMENTAL
Intervention: F2 colloidal nanosuspension (EUD RS 100)
Number of subjects: 0
Study 19853420 — intervention group
Group type: EXPERIMENTAL
Intervention: F5 colloidal nanosuspension (EUD RL 100)
Number of subjects: 0
Study 19853420 — intervention group
Group type: COMPARATOR
Intervention: Zovirax (commercial product)
Number of subjects: 0
Study 17487633 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of a financial incentive
Number of subjects: 0
Study 17487633 — intervention group
Group type: COMPARATOR
Intervention: Reduction of logistical barriers
Number of subjects: 0
Study 15784492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous supplementary nutrition (1000 kcal/day for 3 days, followed by oral supplementary nutrition (400 kcal/day for 7 days))
Number of subjects: 80
Study 15784492 — intervention group
Group type: COMPARATOR
Intervention: Ordinary hospital food and beverage (Control group)
Number of subjects: 80
Study 11897546 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% human albumin 50 ml
Number of subjects: 20
Study 11897546 — intervention group
Group type: COMPARATOR
Intervention: Furosemide 40 mg
Number of subjects: 20
Study 10483385 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 0
Study 10483385 — intervention group
Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 0
Study 10483385 — intervention group
Group type: COMPARATOR
Intervention: Naproxen sodium
Number of subjects: 0
Study 10483385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7916403 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-2 (1 MU) with hepatitis B vaccine (20 micrograms)
Number of subjects: 52
Study 7916403 — intervention group
Group type: COMPARATOR
Intervention: Placebo with hepatitis B vaccine (20 micrograms)
Number of subjects: 52
Study 2802121 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraclavicular brachial plexus block with prilocaine 1% and bupivacaine 0.5%
Number of subjects: 80
Study 2802121 — intervention group
Group type: COMPARATOR
Intervention: Supraclavicular brachial plexus block with prilocaine 1% and discrete nerve blocks with bupivacaine 0.5%
Number of subjects: 80
Study 1148090 — intervention group
Group type: EXPERIMENTAL
Intervention: Propanidid and lignocaine
Number of subjects: 0
Study 1148090 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone and suxamethonium
Number of subjects: 0
Study 31033364 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 220-750 mg/day
Number of subjects: 1494
Study 31033364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1494
Study 31033364 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 1494
Study 31033364 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 1494
Study 28821469 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletic coach-delivered ARA/SV prevention program
Number of subjects: 973
Study 26722699 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health training for care-staff
Number of subjects: 162
Study 26722699 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaled up oral health training for all staff
Number of subjects: 162
Study 26722699 — intervention group
Group type: EXPERIMENTAL
Intervention: Second training cycle including all staff
Number of subjects: 162
Study 26722699 — intervention group
Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 162
Study 23128815 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonothrombolysis using 2 diagnostic probes and bilateral monitoring
Number of subjects: 12
Study 23128815 — intervention group
Group type: COMPARATOR
Intervention: Standard sonothrombolysis
Number of subjects: 12
Study 22314690 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 24
Study 22314690 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lidocaine
Number of subjects: 24
Study 22314690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 20594330 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (Ex)
Number of subjects: 31
Study 20594330 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise (NEx)
Number of subjects: 31
Study 20594330 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Ex and NEx)
Number of subjects: 31
Study 17944889 — intervention group
Group type: EXPERIMENTAL
Intervention: Banxia houpu tang (BHT)
Number of subjects: 104
Study 17944889 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 104
Study 15857739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 523
Study 12160514 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0
Study 12160514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9477056 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-45 microg intrathecal fentanyl
Number of subjects: 84
Study 9477056 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg intrathecal fentanyl
Number of subjects: 84
Study 9477056 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl
Number of subjects: 84
Study 7890075 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized administration of hCG at the onset of the endogenous LH rise (J group)
Number of subjects: 148
Study 7890075 — intervention group
Group type: COMPARATOR
Intervention: Non-synchronized administration of hCG (non-J group)
Number of subjects: 148
Study 1854108 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (loading dose followed by routine infusion, n = 65)
Number of subjects: 133
Study 1854108 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equal volume as loading dose and infusion, n = 68)
Number of subjects: 133
Study 1854108 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (n = 65)
Number of subjects: 133
Study 1854108 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 68)
Number of subjects: 133
Study 6661511 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxalol solution (100 mg)
Number of subjects: 10
Study 6661511 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxalol tablet formulation (100 mg)
Number of subjects: 10
Study 6661511 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxalol intravenous (100 mg)
Number of subjects: 10
Study 31770771 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants reported the Gabor orientation while ignoring the vowel sound (Experiment 1)
Number of subjects: 0
Study 31770771 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants attended to both modalities (Experiments 2 and 3)
Number of subjects: 0
Study 31770771 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous stimulus alone
Number of subjects: 0
Study 31770771 — intervention group
Group type: EXPERIMENTAL
Intervention: No-response trials interleaved (Experiment 3)
Number of subjects: 0
Study 27687644 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 42
Study 27687644 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (Control)
Number of subjects: 42
Study 27256183 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic prostatectomy (RP)
Number of subjects: 65
Study 27256183 — intervention group
Group type: COMPARATOR
Intervention: Suprapubic prostatectomy (SP)
Number of subjects: 65
Study 26954517 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid testing (VIKIA-HBsAg/Quick Profile anti-HBsAb) with confirmatory serology (R+S)
Number of subjects: 409
Study 26954517 — intervention group
Group type: COMPARATOR
Intervention: Standard serology (S)
Number of subjects: 409
Study 26954517 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid testing (VIKIA-HBsAg)
Number of subjects: 409
Study 26954517 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HBsAb Quick Profile rapid test
Number of subjects: 409
Study 26954517 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid testing (R+S)
Number of subjects: 409
Study 23915701 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial free forearm flap
Number of subjects: 50